Pfizer Inc. and the company’s German partner BioNTech SE on March 15 filed an application with U.S. regulators seeking emergency use authorization for a second booster shot of their COVID-19 vaccine for people aged 65 and older.
The U.S. Centers for Disease Control and Prevention (CDC) on Sept. 24 backed a booster shot of the Pfizer and BioNTech Covid-19 vaccine for Americans aged 65 and older, adults with underlying medical conditions and adults in high-risk working and institutional settings.
Advisers to the U.S. Food and Drug Administration voted on Sept. 17 to recommend Covid-19 vaccine booster shots for Americans 65 and older and those at high risk of severe illness, after overwhelmingly rejecting a call for broader approval.
Younger adults are seeking out Covid-19 vaccines at a slower rate than older adults, and if that pace of vaccination continues through August, vaccine coverage among younger adults will not reach levels achieved with older adults, U.S. Centers for Disease Control and Prevention (CDC) reported on June 21.
The U.S. Food and Drug Administration issued emergency use authorization for Regeneron Pharmaceuticals Inc.’s Covid-19 antibody therapy, an experimental treatment given to U.S. President Donald Trump that he said helped cure him of the disease.
U.S. hospitals to restrict Lilly Covid-19 antibody treatment due to limited supply
Adults 65 and Older, Antibodies, Bamlanivimab (LY-CoV555), Coronavirus Disease (COVID-19) Pandemic, Coronavirus Infections, COVID-19 Antibodies, Donald Trump, Eli Lilly, Emergency Use Authorization, FDA, Federal Government, Healthcare Physicians, Hospitalized COVID-19 Patients, Hospitals, Immune System, Regeneron Pharmaceuticals, United StatesU.S. hospitals, weighing high demand and tight supplies, said they may limit use of the new Eli Lilly and Co. nantibody drug bamlanivimab to Covid-19 patients with multiple risk factors for serious illness or to those whose immune systems have not begun to fight the infection.
How Effective Will Lilly’s Bamlanivimab be in the Battle Against Covid-19?
Adults 65 and Older, Analysis, Bamlanivimab (LY-CoV555), Clinical Data, Clinical Trials, Coronavirus Disease 2019 (COVID-19), Emergency Use Authorization, FDA, Hospitalized COVID-19 Patients, Humanized IgG1 monoclonal antibody, Monoclonal Antibodies, R&D, ReutersThere are some questions about how effective Eli Lilly’s antibody neutralizing antibody bamlanivimab (LY-CoV555) will prove to be in the battle against Covid-19 due to labeling limitations.
A combination of Canadian drug developer Medicago’s experimental Covid-19 vaccine and a booster from Britain’s GlaxoSmithKline will enter a large study with more than 30,000 volunteers in 2020.
U.S. allows emergency use of first Covid-19 antibody drug
Adults 65 and Older, Business, Clinical Trials, COVID-19 antibody drugs, Dr. Anthony Fauci (Director), Emergency Use Authorization, FDA, Hospitalized COVID-19 Patients, Monoclonal Antibodies, R&D, Regeneron Pharmaceuticals, Shares, White HouseU.S. regulators authorized emergency use of the first experimental antibody drug for Covid-19 in patients who are not hospitalized but are at risk of serious illness because of their age or other conditions.
Seqirus snagged U.S. FDA approval for Fluad Quadrivalent, the first quadrivalent adjuvanted influenza vaccine developed to help protect adults 65 years and older against seasonal influenza.